Concepedia

Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses

Rodrigo Alonso-Navarro, Margarita Ramírez, Mar Masiá, Roger Paredes, Rocío Montejano, Marina Povar-Echeverría, Jordi Carratalà, Miguel Salavert, Enrique Bernal, Carlos Dueñas,

BMC Infectious Diseases · 2023 · 11 citations · 23 references

DOIFull text

Open access

Abstract

For patients admitted to the hospital with COVID-19, the prescription of remdesivir within 5 days from symptoms onset diminishes the need of ICU admission.

References

23

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel, Kay M Tomashek, Lori E. Dodd et al. · New England Journal of Medicine · 2020 · 7.6K citations · Full text

Temporal dynamics in viral shedding and transmissibility of COVID-19

Xi He, Eric H. Y. Lau, Peng Wu et al. · Nature Medicine · 2020 · 4.6K citations · Full text

, , +5

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Yeming Wang, Dingyu Zhang, Guanhua Du et al. · The Lancet · 2020 · 3.6K citations · Full text

, , +9

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

New England Journal of Medicine · 2020 · 2.6K citations · Full text

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

New England Journal of Medicine · 2022 · 2.1K citations · Full text